Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
LTGO
Strong SellLatigo Biotherapeutics, Inc. · Healthcare · United States · $1.4B
8
StockRankGet insider-trade alerts
Q
29
V
25
M
25
P/E (TTM)
—
ROE
—
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
Latigo Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel non-opioid pain treatments. The company utilizes a specialized pipeline aimed at addressing the significant medical need for effective, non-addictive alternatives in the pain management market.
Loading 1Y...
PRICE (1Y)+32.8%
Close
$24.23
RSI (14)
79.7
SCORE BREAKDOWN
Quality
29
ROIC
-193.4%2.9
ROE
—N/A
GP/Assets
—N/A
Op. Margin
0.0%40.1
FCF/Assets
-129.4%1.3
Piotroski
239.9
Int. Cover
—N/A
D/E Ratio
0.02x81.4
Current Ratio
3.23x57.4
Value
25
P/E (TTM)
—N/A
EV/EBITDA
-3.5x25.0
P/FCF
—N/A
P/B
-0.6x25.0
P/S
—N/A
Div Yield
—N/A
Momentum
25
52W High %
—N/A
RS 6M
—N/A
SMA 50/200
—N/A
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$1.4B
P/E (Forward)
—
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of LTGO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| LTGO | Latigo Biotherapeutics, Inc.(you) | $1.4B | 8 | Strong Sell |
| SPTX | Seaport Therapeutics, Inc. | $1.3B | 9 | Strong Sell |
| MAZE | Maze Therapeutics, Inc. | $1.6B | 9 | Strong Sell |
| TYRA | Tyra Biosciences, Inc. | $1.6B | 10 | Strong Sell |
| AKTS | Aktis Oncology, Inc. | $1.4B | 12 | Strong Sell |
| TRAX | First Tracks Biotherapeutics, Inc. | $1.5B | 6 | Strong Sell |
| CRVS | Corvus Pharmaceuticals, Inc. | $1.2B | 9 | Strong Sell |
| SANA | Sana Biotechnology, Inc. | $1.1B | 7 | Strong Sell |
| NTLA | Intellia Therapeutics, Inc. | $1.8B | 8 | Strong Sell |
| OBX | Obsidian Therapeutics, Inc. | $1.2B | 7 | Strong Sell |
Peer medians: ROE -25.6% · P/E 29.5x · Gross margin 58.7%